Special Issue

Noroviruses

Message from the Guest Editors

Noroviruses are the leading cause of severe childhood diarrhea and foodborne outbreaks across the globe. Despite their massive disease burden, the development of vaccines and antiviral therapies has been hindered by the lack of cell culture and animal models of infection. However, the past 15 years has been an exciting time for norovirus research, and major progress has been made in overcoming these obstacles. The discovery of culturable murine noroviruses paved the way for substantial insight into replication strategies and the pathogenesis of noroviruses. More recently, two culture systems have been developed for human noroviruses. Finally, the use of virus-like particles as vaccine candidates and the development of antiviral therapies have progressed significantly. In this Special Issue, we will review the major discoveries in the norovirus field from the past 15 years, as well as providing several primary research articles highlighting the continuing progress being made by our community.

Guest Editors

Prof. Dr. Stephanie Karst

Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA

Assoc. Prof. Dr. Christiane Wobus

Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, 48109, USA

Deadline for manuscript submissions

closed (31 January 2019)

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/17968

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/viruses

Viruses

an Open Access Journal by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/viruses

About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed
HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).